Therefore, on the basis of antihypertensive therapy, mTOR inhibitors may provide a new therapeutic candidate for delaying myocardial remodeling and cardiac insufficiency in postmenopausal hypertensive women. The gene discussed is MTOR; the disease is heart failure.